PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ler the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

8 + 4

Refs.

## **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

**Application Number** 10/627,372 Filing Date July 24, 2003 First Named Inventor Harrihar A. PERSHADSINGH Art Unit 1614 **Examiner Name** K. Weddington Attorney Docket Number 421842000400

ENCLOSURES (Check all that apply)							
Fee Transmittal Form (1 page in duplicate)		Drawing(s)	After Allowance Communication to TC				
Fee Attached		Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply		Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After	Final	Petition to Convert to a Provisional Application	Proprietary Information				
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter				
Extension	of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):				
Express Abandonment Request		Request for Refund	1. Form PTO/SB/08a/b (1 page in duplicate)				
x Information (3 pages)	Disclosure Statement	CD, Number of CD(s)	References (4)     Return Receipt Postcard				
Certified Copy of Priority Document(s)		Landscape Table on CD					
	issing Parts/ Application	Remarks					
	y to Missing Parts under FR 1.52 or 1.53						
	SIGNAT	 URE OF APPLICANT, ATTORNEY, (	DR AGENT				
Firm Name							
Signature Manteun Basy							
Printed name Shantanu Basu			·				
Date	October 26, 2005	Reg. No	D. 43,318				

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV544978377US, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown (Georgina Matos)

Dated: October 26, 2005

Signature:

PTO/SB/17 (12-04v2)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).			Application Nu	ımber	10/627,372			
FEE 7	Filing Date		July 24, 2003					
	First Named In	nventor	Hamihar A. PERSHADSINGH					
	Examiner Nam	е	K. Weddington	)				
X Applicant clair	ms small entity status. S	See 37 CFR 1.27	Art Unit		1614			
TOTAL AMOUNT	OF PAYMENT	(\$) 180.00	Attorney Docke	et No.	421842000400	)		
METHOD OF PA	YMENT (check all the	nat apply)		*				
Check C	Credit Card M	Ioney Order No	one Other	(please iden	tify):			
x Deposit Accoun	t Deposit Account Numb	er: 03-1952 Deposit Ad	count Name:	Mo	rrison & Foerst	er LLP		
For the above	e-identified deposit a	account, the Director	s hereby authori	zed to: (che	ck all that apply)			
x Charg	e fee(s) indicated bel	ow	Char	ge fee(s) in	dicated below, ex	cept for t	he filing fee	
	e any additional fee(s under 37 CFR 1.16 a		x Cred	it any overp	ayments			
FEE CALCULAT	ION		<del>-</del>					
1. BASIC FILING, S	EARCH, AND EXAM	INATION FEES	-		·	-		
	FILING	G FEES SE	ARCH FEES	EXAMI	NATION FEES			
Application Type	Fee (\$)	Small Entity Fee (\$) Fee (	Small Entity Fee (\$)	<u>Fee (\$)</u>	Small Entity Fee (\$)	Fooe I	Paid (\$)	
Utility	300	150 500		200	100	1 663 1	aiu (p)	
Design	200	100 100		130	65			
Plant	200	100 300		160	80		<del></del>	
Reissue	300	150 500		600	300			
Provisional	200	100 0		0	0			
2. EXCESS CLAIM	FEES		_		· ·		Small Entity	
Fee Description						Fee (\$)	Fee (\$)	
Each claim over 20	(including Reissues)			•		50	25	
_	laim over 3 (includin	g Reissues)		•		200	100	
Multiple dependent	claims					360	180	
Total Claims		<del></del>	Paid (\$)	<u>M</u>	ultiple Depende	ent Claims		
27 27 :	=0 x _2	25.00 =	0.00			ee Paid (\$	<u>i)</u>	
		_		18	30.00_	0.00	_	
<u>Indep. Claims</u> 5 - 5 =			Paid (\$)					
		00.00 =	0.00					
3. APPLICATION SIZE FEE  If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer								
listings under 3	7 CFR 1.52(e)), the a	application size fee d	ue is \$250 (\$125	for small e	entity) for each a	dditional 5	0	
sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).								
Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)								
- 100 = /50 (round up to a whole number) x =								
4. OTHER FEE(S)  Non-English Specification, \$130 fee (no small entity discount)								
· ·	filing surcharge): 18	· ·		Disclosure	Statement	18	30.00	
SUBMITTED BY								
Signature	thanton	Sus.	Registration No.	43.318	Telephone	(650) 81	3-5995	

SUBMITTED BY					-
Signature	thanken Sur	Registration No. (Attorney/Agent)	43,318	Telephone	(650) 813-5995
Name (Print/Type)	Shantanu Basu			Date	October 26, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV544978377US, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below

Patent Docket No. 421842000400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: rihar A. PERSHADSINGH

Serial No.: 10/627,372

Filing Date: July 24, 2003

For: NOVEL PPAR LIGANDS THAT DO

NOT CAUSE FLUID RETENTION. EDEMA OR CONGESTIVE HEART

**FAILURE** 

Examiner: K. Weddington

Group Art Unit: 1614

## SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Pursuant to 37 C.F.R. § 1.704(d), I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this Supplemental Information Disclosure Statement.

pa-1019850

The documents listed on the attached Form PTO/SB/08a/b were cited in a Supplementary Partial European Search Report mailed on September 29, 2005, directed to a counterpart international or foreign application and have not been previously cited. A certification under 37 C.F.R. § 1.97(e)(1) follows:

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

This Supplemental Information Disclosure Statement is submitted: With the application; accordingly, no fee or separate requirements are required. Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided. П After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance. A fee is required. A check in the amount of is enclosed. П A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate. П A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due. 冈 After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of is enclosed.  $\boxtimes$ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

2

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>421842000400</u>.

Dated: October 26, 2005

Respectfully submitted,

Shantanu Basu

Registration No.: 43,318

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-5995



Complete if Known Substitute for form 1449/PTO Application Number 10/627,372 Filing Date July 24, 2003 INFORMATION DISCLOSURE Harrihar A. PERSHADSINGH First Named Inventor STATEMENT BY APPLICANT Art Unit 1614 (Use as many she ets as necessary) K. Weddington Examiner Name 1 Attorney Docket Number 421842000400 Sheet 1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		1				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1.	WO-01/82858-A2, A3	11-08-2001	IPF Pharmaceuticals GMBH et al.	Translation of Abstract Only			

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. The reign of the reign of the tail issued the document, by the two-letter code (MPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials						
	2.	Asmar, R. et al. (April 2001). "Effects of Telmisartan on Arterial Compliance and Endothelial Function in Type 2 Diabetes Patients with Essential Hypertension," <i>American Journal of Hypertension</i> 14(4):114A, Abstract P-254, one page.				
	3.	Supplementary Partial European Search Report mailed September 29, 2005, for EP Patent Application No. 03785060.9, filed August 8, 2003, five pages.				
	4.	Wienen, W. et al. (March 2001). "Comparative Antihypertensive and Renoprotective Effects of Telmisartan and Lisinopril After Long-Term Treatment in Hypertensive Diabetic Rats," <i>J. of the Renin-Angiotensin- Aldosterone System</i> 2(1):31-36.				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	=	 •	Date	
Signature			Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.